Researcher Profiles

Return to member profile

X. F. Steven Zheng, PhD

Publications since 2011

Wang, R. Ganesan, S. Zheng, X. F. Yin and Yang of 4E-BP1 in Cancer. Cell Cycle, In process, . (PMID: 27096536)

Yang, X. Z. Li, X. X. Zhang, Y. J. Rodriguez-Rodriguez, L. Xiang, M. Q. Wang, H. Y. Zheng, X. F. Rab1 in cell signaling, cancer and other diseases. Oncogene, In process, . (PMID: 27041585)

Hu, J. Y. Yi, W. Zhang, M. Y. Xu, R. Zeng, L. S. Long, X. R. Zhou, X. M. Zheng, X. S. Kang, Y. Wang, H. Y. MicroRNA-711 is a prognostic factor for poor overall survival and has an oncogenic role in breast cancer. Oncol Lett, 11:2155-2163, . (PMID: 26998141, PMCID: PMC4774458)

Zhang, Y. Wang, X. Qin, X. Wang, X. Liu, F. White, E. Zheng, X. F. PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer. EBioMedicine, 2:1944-1956, . (PMID: 26844273, PMCID: PMC4703732)

Li, Y. Wang, H. Y. Zheng, X. F. Rab1 GTPases as oncogenes. Aging (Albany NY), In process, . (PMID: 26590354)

Che, M. Wang, R. Wang, H. Y. Zheng, X. F. Expanding roles of superoxide dismutases in cell regulation and cancer. Drug Discov Today, In process, . (PMID: 26475962)

Meng, L. H. Zheng, X. F. Toward rapamycin analog (rapalog)-based precision cancer therapy. Acta Pharmacol Sin, In process, . (PMID: 26299952)

Wu, T. J. Wang, X. Zhang, Y. Meng, L. Kerrigan, J. E. Burley, S. K. Zheng, X. F. Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase. Cell Rep, In process, . (PMID: 25865887)

Cha, Y. L. Li, P. D. Yuan, L. J. Zhang, M. Y. Zhang, Y. J. Rao, H. L. Zhang, H. Z. Zheng, X. F. Wang, H. Y. EIF4EBP1 Overexpression Is Associated with Poor Survival and Disease Progression in Patients with Hepatocellular Carcinoma. PLoS One, 10:e0117493, . (PMID: 25658620)

Thomas, J. D. Zhang, Y. J. Wei, Y. H. Cho, J. H. Morris, L. E. Wang, H. Y. Zheng, X. F. Rab1A Is an mTORC1 Activator and a Colorectal Oncogene. Cancer Cell, 26:754-769, . (PMID: 25446900)

Tsang, C. K. Liu, Y. Thomas, J. Zhang, Y. Zheng, X. F. Superoxide dismutase 1 acts as a nuclear transcription factor to regulate oxidative stress resistance. Nat Commun, 5:3446, . (PMID: 24647101)

Peng, H. S. Liao, M. B. Zhang, M. Y. Xie, Y. Xu, L. Zhang, Y. J. Zheng, X. F. Wang, H. Y. Chen, Y. F. Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells. PLoS One, 9:e100814, . (PMID: 24956259, PMCID: PMC4067386)

Wei, R. Huang, G. L. Zhang, M. Y. Li, B. K. Zhang, H. Z. Shi, M. Chen, X. Q. Huang, L. Zhou, Q. M. Jia, W. H. Zheng, X. F. Yuan, Y. F. Wang, H. Y. Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma. Clin Cancer Res, 19:4780-4791, . (PMID: 23812667)

Don, A. S. Tsang, C. K. Kazdoba, T. M. D'Arcangelo, G. Young, W. Zheng, X. F. Targeting mTOR as a novel therapeutic strategy for traumatic CNS injuries. Drug Discov Today, 17:861-868, . (PMID: 22569182, PMCID: PMC3411916)

Zheng, X. F. Chemoprevention of age-related macular regeneration (AMD) with rapamycin. Aging (Albany NY), 4:375-376, . (PMID: 22796653, PMCID: PMC3409673)

Zhang, Y. Zheng, X. F. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle, 11:594-603, . (PMID: 22262166, PMCID: PMC3315097)

Zhang, Y. J. Duan, Y. Zheng, X. F. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today, 16:325-331, . (PMID: 21333749, PMCID: PMC3073023)

Arachchige Don, A. S. Zheng, X. F. Recent Clinical Trials of mTOR-Targeted Cancer Therapies. Rev Recent Clin Trials, 6:24-35, . (PMID: 20868343)

Wei, Y. Zheng, X. F. Nutritional control of cell growth via TOR signaling in budding yeast. Methods Mol Biol, 759:307-319, . (PMID: 21863495)